Patent classifications
C12N15/03
Mutant organophosphorus acid anhydrolase enzymes with stereospecificity on Sarin enantiomers and uses thereof
Disclosed herein are non-wild-type organophosphorus acid anhydrolases having three site mutations, methods of production, and methods of use to effectively degrade toxic chemicals such as((RS)-Propan-2-yl methylphosphonofluoridate)(Sarin) and other organophosphorus compounds. Also provided are organophosphorus acid anhydrolase mutants capable of degrading Sarin with distinct selective stereospecificity preferences differing from the wild-type organophosphorus acid anhydrolase
Mutant organophosphorus acid anhydrolase enzymes with stereospecificity on Sarin enantiomers and uses thereof
Disclosed herein are non-wild-type organophosphorus acid anhydrolases having three site mutations, methods of production, and methods of use to effectively degrade toxic chemicals such as((RS)-Propan-2-yl methylphosphonofluoridate)(Sarin) and other organophosphorus compounds. Also provided are organophosphorus acid anhydrolase mutants capable of degrading Sarin with distinct selective stereospecificity preferences differing from the wild-type organophosphorus acid anhydrolase
Host Cells with Artificial Endosymbionts
The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.
Host Cells with Artificial Endosymbionts
The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.
Host cells with artificial endosymbionts
The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria.
Host cells with artificial endosymbionts
The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell through at least five cell divisions, and methods of introducing such single-celled organisms into eukaryotic cells. The invention also provides methods of using such eukaryotic cells. The invention further provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetotactic bacteria.
Prokaryotic Collagen Therapeutics for Postoperative Adhesions
The present invention includes a synthetic collagen that facilitates adhesion prevention and methods of use thereof. The present invention includes a prokaryotic collagen that facilitates adhesion prevention and treatment and methods of use thereof. The prokaryotic collagen includes an isolated and purified triple helical backbone protein that facilitates adhesion prevention: one or more alteration in a triple helical backbone protein sequence, and one or more binding motifs, wherein the isolated and purified triple helical backbone protein facilitates adhesion prevention.
Prokaryotic Collagen Therapeutics for Postoperative Adhesions
The present invention includes a synthetic collagen that facilitates adhesion prevention and methods of use thereof. The present invention includes a prokaryotic collagen that facilitates adhesion prevention and treatment and methods of use thereof. The prokaryotic collagen includes an isolated and purified triple helical backbone protein that facilitates adhesion prevention: one or more alteration in a triple helical backbone protein sequence, and one or more binding motifs, wherein the isolated and purified triple helical backbone protein facilitates adhesion prevention.
Host cells with artificial endosymbionts
The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.
Host cells with artificial endosymbionts
The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.